Dr. John Bilello has over 25 years of
experience in the pharmaceutical
industry, the biotechnology sector,
and academic and government
laboratories. He was an Associate
Professor at the University of
Maryland School of Medicine and Albany
Medical College. Dr. Bilello joined
GlaxoSmithKline (GSK), where he was
the Director of Technology Development
in Translational Medicine and
Genetics. John assessed external
technologies in his technology
development role, identifying new
investment opportunities for GSK’s
Technology Investment Board. His work
with GSK’s Human Biomarker
Laboratories led to tools for
stratifying patients and monitoring
efficacy in clinical studies.
Specifically, he developed biomarkers
for enabling studies of new
therapeutics for COPD,
diabetes/metabolic syndrome, migraine,
and neurodegenerative diseases. Before
joining GSK, he was a biochemist at
Roche Pharmaceuticals, a Volkswagen
Fellow at the University of Hamburg
(Germany), and the Director of
Preclinical Research and Development
at two successful biotechnology
companies (SRA Lifesciences and Virco
Laboratories). As an enthusiastic
entrepreneur, John was a founder and
Chief Scientific Officer of Ridge
Diagnostics, which developed and
commercialized a diagnostic for major
depressive disorder. At Ridge, he was
an inventor on multiple US and
international patents and processes.
John has authored over seventy
publications in refereed journals and
more than ten book chapters. An
internationally recognized scientist,
he was a member of the editorial board
for *Antimicrobial Agents and
Chemotherapy* (1995-2009). In addition
to an established track record of
innovative basic and clinical
research, Dr. Bilello has extensive
experience in project and
organizational management. John was a
co-founder and Managing Partner of
Innovalyst LLC, a small business
accelerator focused on catalyzing
product innovation in the Life
Sciences.